[en] OBJECTIVES: Corticosteroid dependency in Crohn's disease (CD) is characterized by the need for chronic use of corticosteroids to maintain clinical remission. Several definitions have been used. Depending on the definition, 10-30% of the patients are considered as corticosteroid dependent. The aim of the study was to define a clinical pattern of corticosteroid dependent CD patients. PATIENTS AND METHODS: Epidemiological and clinical characteristics were retrospectively compared between 20 corticosteroid dependent CD patients and 248 non-corticosteroid dependent CD patients by using univariate and multivariate analyses. Corticosteroid dependency was defined either by two successive relapses during the 2 months after discontinuing glucocorticoids (n=5) or by two successive relapses at dose tapering, after successful treatment of a flare-up by using glucocorticoids (n=15). RESULTS: Corticosteroid dependent CD patients were younger at diagnosis (P < 0.001), and were characterized by a higher frequency of colonic location (P< 0.05), but lower frequency of ileal location (P < 0.01), and higher ano-perineal location (P < 0.05). They were also more frequently smokers (P< 0.05) and users of contraceptive pills (P< 0.01). The inflammatory type of the disease was increased (P < 0.01), while the fibrostenotic type was decreased (P < 0.001) in corticosteroid dependent CD patients. By multivariate analysis, a smoking habit (P < 0.01), a colonic location (P < 0.05), a non-fibrostenotic type (P< 0.05) and a younger age at diagnosis (P< 0.05) were shown to be independently associated with corticosteroid dependency. CONCLUSIONS: This study suggests a clinical pattern associated with corticosteroid dependency. Whether this clinical pattern is simply associated with the dependency, or whether a primary decrease of corticosensitivity produces this clinical pattern, is not known. Further prospective studies will have to determine whether the presence of these clinical characteristics is predictive of corticosteroid dependency and whether this prediction will be useful for the management of this condition.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Franchimont, D. P.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Croes, F.
Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
Clinical Pattern of Corticosteroid Dependent Crohn's Disease
Publication date :
October 1998
Journal title :
European Journal of Gastroenterology and Hepatology
Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 20:1351-1362.
Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Int Med 1993; 119:1198-1208.
Chrousos GP, Castro M, Leung DM, Webster E, Kino T, Bamberger C, et al. Molecular mechanisms of glucocorticoid resistance and hypersensitivity. Am J Crit Care Med 1996; 154:S39-S44.
Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor. Function and tissue sensitivity to glucocorticoids. Endocrine Rev 1996; 17:245-261.
Satsangi J, Jewell DP, Rosenberg WMC, Bell JI. Genetics of inflammatory bowel disease. Gut 1994; 35:696-700.
Sher ER, Leung DYM, Surs W, Kam JC, Zieg G, Kamada AK, et al. Steroid resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93:33-39.
Sachar DB, Andrews HA, Farmer RG, Pallone F, Pena AS, Prantera C, et al. Proposed classification of patients subgroups in Crohn's disease. Gastroenterol Int 1992; 3:142-145.
Landi B, N'Guyen Anh T, Cortot A, Soule JC, Rene E, Gendre JP, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. Gastroenterology 1992; 102:1647-1653.
Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Gastroenterology 1990; 98:811-818.
Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1984; 86:249-266.
Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et al. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979; 77:847-869.
Modigliani R. Corticosteroid therapy in active Crohn's disease. IBD and Salicylates, Research and Clinical Forums 1993; 14:121-128.
Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996; 110:688-693.
Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Int Med 1995; 122:132-142.
Present DH, Korelitz BI, Wish N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. N Engl J Med 1980; 302:981-987.
Ewe K, Press AG, Singe CC, Stufler M, Uebershaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105:367-372.
Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Dig Dis 1975; 20:721-726.
Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332:292-297.
Feagan BG, McDonald JWD, Rochon J, Laupacis A, Fedorak RN, Kinnear D, et al. Low dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330:1846-1851.
Brynskov J, Freund L, Rasmussen SM, Lauriten K, Shaffalitsky De Muckadell O, Williams N, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active Crohn's disease. N Engl J Med 1989; 321:845-850.
Van Dullemen HM, Van Deventer SJH, Hommes DW, Bull HA, Jansen J, Tytgat GNJ, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-135.
Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Shreiber S. Treatment with tumor necrosis factor inhibitor oxypentifylline does not improve corticosteroid-dependent chronic active Crohn's disease. Gut 1997; 40:470-474.
Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35:360-362.
Rhodes JM, Cockel R, Allan RN, Hawker PC, Dawson J, Elias E. Colonic Crohn's disease and use of oral contraception. BMJ 1 984; 288:595-596.
Costas M, Trapp T, Pereda MP, Sauer J, Rupprecht R, Nahmod VE, et al. Molecular and functional evidence for in vitro cytokine enhancement of human and murine target cell sensitivity to glucocorticoids. J Clin Invest 1996; 98:1409-1416.
Rakasz E, Gal A, Biro J, Balas G, Falus A. Modulation of glucocorticosteroid binding in human lymphoid, monocytoid and hepatoma cell lines by inflammatory cytokines IL-1β, IL-6 and TNFα. Scand J Immunol 1993; 37:684-689.
Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor binding affinity and T-cell response to glucocorticoids. J Immunol 1993; 7:3460-3466.
Spann DS, Szefler J, Surs W, Doherty DE, Leung DY. A novel action of interleukin-13; induction of diminished monocyte glucocorticoid receptor binding affinity. J Immunol 1996; 157:2654-2659.
Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NFkB and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91:752-756.
Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappaB activity through induction of I kappa B synthesis. Science 1995; 270:283-286.
Barnes PJ, Karin M. Nuclear factor-kB. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.
Neurath MF, Petterson S, Meyer zum Büschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nature Med 1996; 9:998-1004.
Van der Burg B, Liden J, Okret S, Delaunay F, Wissink S, Van der Saag PT, Gustafsson JA. Nuclear factor-κB repression in anti-inflammation and immunosuppression by glucocorticoids. Trends Endocrinol Metab 1997; 8:152-157.
Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996; 110:424-431.
